Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR

International Journal of Clinical Oncology

Volumn 21, Issue 5, 2016, Pages 981-988

  Ashida, Atsuko ^a   Sakaizawa, Kaori ^a   Mikoshiba, Asuka ^a   Uhara, Hisashi ^a   Okuyama, Ryuhei ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BRAF; castPCR; Circulating tumor derived DNA; Melanoma; Therapeutic monitoring

Indexed keywords

B RAF KINASE; CISPLATIN; CYSTEINYLDOPA; DACARBAZINE; GENOMIC DNA; IPILIMUMAB; LACTATE DEHYDROGENASE; NIMUSTINE; DNA; TUMOR MARKER;

ADULT; AGED; ALLELE; ARTICLE; BLOOD; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; JAPANESE (PEOPLE); LACTATE DEHYDROGENASE BLOOD LEVEL; LIMIT OF QUANTITATION; MALE; MELANOMA; MELANOMA CELL LINE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; YOUNG ADULT; GENETICS; MUTATION; PATHOLOGY; PROCEDURES; SECONDARY; SKIN TUMOR; TUMOR EMBOLISM;

ADULT; AGED; ALLELES; BIOMARKERS, TUMOR; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TUMOR BURDEN; YOUNG ADULT;

EID: 84962142349     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-016-0976-y     Document Type: Article

References (25)

1. Menzies AM, Long GV (2014) Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 15:e371–e381
2. Diaz-Lagares A, Alegre E, Arroyo A et al (2011) Evaluation of multiple serum markers in advanced melanoma. Tumour Biol 32:1155–1161
3. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C et al (2014) Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clin Chim Acta 429:168–174
4. Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437
5. Dawson SJ, Tsui DW, Murtaza M et al (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209
6. Oxnard GR, Paweletz CP, Kuang Y et al (2014) Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20:1698–1705
7. Taly V, Pekin D, Benhaim L et al (2013) Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 59:1722–1731
8. Thierry AR, Mouliere F, El Messaoudi S et al (2014) Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 20:430–435
9. Huggett JF, Whale A (2013) Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin Chem 59:1691–1693
10. Siravegna G, Bardelli A (2014) Minimal residual disease in breast cancer: in blood veritas. Clin Cancer Res 20:2505–2507
11. Ashida A, Uhara H, Kiniwa Y et al (2012) Assessment of BRAF and KIT mutations in Japanese melanoma patients. J Dermatol Sci 66:240–242
12. Cheng SP, Hsu YC, Liu CL et al (2014) Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma. Ann Surg Oncol 21[Suppl 4]:S619–S626
13. Didelot A, Le Corre D, Luscan A et al (2012) Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol 92:275–280
14. Ashida A, Uhara H, Mikoshiba A et al (2015) Melanoma with BRAF mutation in circulating cell-free DNA despite no mutation in the primary lesion: a case report. Acta Derm Venereol 96:128–129
15. Schreuer M, Meersseman G, van Den Herrewegen S et al (2016) Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. Melanoma Res 26:157–163
16. Wakamatsu K, Ito S, Horikoshi T (1991) Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression. Melanoma Res 1:141–147
17. Sakaizawa K, Goto Y, Kiniwa Y et al (2012) Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 106:939–946
18. Stoecklein NH, Hosch SB, Bezler M et al (2008) Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13:441–453
19. Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990
20. Taniguchi K, Uchida J, Nishino K et al (2011) Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 17:7808–7815
21. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C et al (2015) Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem 61:297–304
22. Kukita Y, Uchida J, Oba S et al (2013) Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One 8:e81468
23. Wakamatsu K, Kageshita T, Furue M et al (2002) Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years’ experience. Melanoma Res 12:245–253
24. Colombino M, Capone M, Lissia A et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30:2522–2529
25. Saint-Jean M, Quereux G, Nguyen JM et al (2014) Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy? J Invest Dermatol 134:1468–1470